Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of setanaxib in primary biliary cholangitis with elevated liver stiffness
MOH_2022-03-07_010314Phase 2Active, not recruiting
- Sponsor
- Calliditas Therapeutics AB
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of setanaxib in primary biliary cholangitis (PBC) (3 arms), sponsored by Calliditas Therapeutics AB. Primary endpoint: Reduction in alkaline phosphatase. Started Feb 2022; status: active, not recruiting.
02
Drugs
setanaxib
03
Conditions
primary biliary cholangitis (PBC)
Beyond the preview
Go deeper on MOH_2022-03-07_010314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-03-07_010314.